A new Eli Lilly analysis found that its daily GLP-1 pill, Foundayo (orforglipron), was linked to slightly more weight loss and blood sugar lowering than the higher 25 mg dose of oral semaglutide in adults with type 2 diabetes. At 52 weeks, people on Foundayo 17.2 mg lost 1.5% more body weight and lowered A1C by 0.3 percentage points more, according to Lilly's release on the indirect comparison. The comparison was indirect, meaning the two drugs were never tested against each other in the same study.
The 25 mg semaglutide tablet is the dose sold in the U.S. as the Wegovy pill for weight management. For people deciding between two daily pills, the gap is small enough that dosing routines, stomach side effects, and cost may matter as much as the efficacy numbers.
